Showing 1831-1840 of 2320 results for "".
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of
- ISHRS: New Guidelines for Hair Restoration Surgery During COVID-19 Pandemichttps://practicaldermatology.com/news/ishrs-new-guidelines-for-hair-restoration-surgery-during-covid-19-pandemic-1/2460469/Hair restoration surgeries can proceed safely in the midst of the ongoing COVID-19 pandemic, the International Society of Hair Restoration Surgery (ISHRS) says. The organization has established suggested protocols for resuming hair restoration practices and offers patients guidance in f
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
- FDA Approves New Dupixent Pre-filled Pen Designed to Support More Convenient Self-Administrationhttps://practicaldermatology.com/news/fda-approves-new-dupixent-pre-filled-pen-designed-to-support-more-convenient-self-administration/2460444/The FDA has approved a 300mg single-dose pre-filled pen for Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab). The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma
- Physician-Created App Unveils Remote Check-In Feature to Prevent Spread of COVID-19 in Medical Practiceshttps://practicaldermatology.com/news/physician-created-app-unveils-remote-check-in-feature-to-prevent-spread-of-covid-19-in-medical-practices/2460436/DocClocker, an app that allows patients to receive real-time wait time reporting of their medical providers, enabling patients to avoid long waits in medical waiting rooms—limiting COVID-19 exposure risks. The company recently launched a new feature for the app—DocClocker Remote Check
- Soliton’s Rapid Acoustic Pulse Device Improves Cellulite in Pivotal Studyhttps://practicaldermatology.com/news/solitons-rapid-acoustic-pulse-device-improves-cellulite-in-study/2460422/Patients treated with Soliton’s investigational Rapid Acoustic Pulse (RAP) device experienced an average 32.5 percent improvement in Cellulite Severity Score, according to newly released data presented via the American Academy of Dermatology (AAD) 2020 VMX Virtual Conference. The
- Phase 3 Study Finds Twice-Weekly Enstilar Foam Safe and Effective for Long-Term Maintenance Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/phase-3-study-finds-twice-weekly-enstilar-foam-safe-and-effective-for-long-term-maintenance-treatment-of-plaque-psoriasis/2460427/LEO Pharma A/S presented results from the Phase 3 PSO-LONG clinical tria, which compared the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) Foam versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.
- Late-Breaking Data: Lilly and Dermira’s Lebrikizumab Improves Itch, Sleep and Quality of Life in ADhttps://practicaldermatology.com/news/late-breaking-data-lilly-and-dermiras-lebrikizumab-improves-itch-sleep-and-quality-of-life-in-ad-1/2460424/Lilly and Dermira’s Lebrikizumab improves itch, sleep and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to a Phase 2b clinical trial presented during a virtual late-breaking, oral session at the American Academy of Dermatology (AAD) 2020 Annual Meetin
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th